IBCSG 56-17 IMpassion030 / ALEXANDRA

  • This is a global Phase III, open-label, randomized, controlled study designed to evaluate the efficacy, safety, and pharmacokinetics of adjuvant treatment with atezolizumab +T-AC compared with T-AC alone in patients with newly diagnosed triple-negative breast cancer who have had curativintent of their primary tumor and are candidates for adjuvant systemic therapy following surgery.

    • Trial Coordinator
      Poonam Jani

      IBCSG Data Management Center/FSTRF
      4033 Maple Road
      Amherst, New York 14226 USA
      Phone: +1 716 834 0900
      Fax: +1 716 833 3990
      Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

      ETOP IBCSG Partners Foundation
      Coordinating Center, Bern, Switzerland
      Phone: +41 31 511 94 00
      Fax: +41 31 511 94 01
      Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

      Targeted Accrual
      2300

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    Member Login